呼吸道感染疾病治療藥物市場：依藥物、適應症、通路分類 - 全球預測 2023-2030

預計2023年全球呼吸道感染疾病治療藥物市場將大幅成長453.3億美元，年複合成長率為7.78%，預計到2030年將達到767億美元。

FPNV定位矩陣

FPNV 定位矩陣對於評估全球呼吸道感染疾病治療市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球呼吸道感染疾病治療藥物市場規模及預測為何？

2.在預測期內，COVID-19對全球呼吸道感染疾病治療藥物市場的阻礙因素與影響有哪些？

3.在預測期內，全球呼吸道感染疾病治療藥物市場需要投資哪些產品/細分市場/應用/領域？

4.全球呼吸道感染疾病藥物市場的競爭策略為何？

5. 全球治療呼吸道感染疾病藥物市場的技術趨勢和法律規範是什麼？

6.全球呼吸道感染疾病治療藥物市場主要廠商的市佔率為何？

7. 哪些型態和策略措施被認為適合進入呼吸道感染疾病藥物全球市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 氣喘和呼吸道感染疾病的報告增加
    • 改變生活方式和老年人口
    • 該領域學名藥和生物相似藥的開發力道加大
  • 抑制因素
    • 季節性展示與檢驗
  • 機會
    • 投資藥物開發和商業化
    • 藥物輸送系統的技術開發
  • 任務
    • 抗菌素抗藥性的出現
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化

第6章 呼吸道感染疾病治療藥品市場（依藥品）

• 抗生素
• 止咳藥
• 鼻減充血劑
• 非類固醇消炎劑

第7章 感染疾病治療藥物市場：依疾病適應症

• 下呼吸道感染疾病
• 上呼吸道感染疾病

第8章 呼吸道感染疾病治療藥物市場：按分銷管道

• 醫院藥房
• 網路藥房
• 零售藥房

第9章 北美和南美呼吸道感染疾病治療藥物市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第10章 亞太呼吸道感染疾病治療市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第11章歐洲、中東和非洲呼吸道感染疾病治療市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第12章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第13章上市公司名單

第14章附錄

• 討論指南
• 關於許可證和定價

The Global Respiratory Tract Infection Therapeutic Market is forecasted to grow significantly, with a projected USD 45.33 billion in 2023 at a CAGR of 7.78% and expected to reach a staggering USD 76.70 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Respiratory Tract Infection Therapeutic Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Respiratory Tract Infection Therapeutic Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drugs, market is studied across Antibiotics, Cough Suppressants, Nasal Decongestants, and Non-Steroidal Anti-Inflammatory Drugs. The Non-Steroidal Anti-Inflammatory Drugs is projected to witness significant market share during forecast period.

Based on Disease Indication, market is studied across Lower Respiratory Tract Infection and Upper Respiratory Tract Infection. The Upper Respiratory Tract Infection is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Online Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Respiratory Tract Infection Therapeutic Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Respiratory Tract Infection Therapeutic Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Respiratory Tract Infection Therapeutic Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Respiratory Tract Infection Therapeutic Market?

4. What is the competitive strategic window for opportunities in the Global Respiratory Tract Infection Therapeutic Market?

5. What are the technology trends and regulatory frameworks in the Global Respiratory Tract Infection Therapeutic Market?

6. What is the market share of the leading vendors in the Global Respiratory Tract Infection Therapeutic Market?

7. What modes and strategic moves are considered suitable for entering the Global Respiratory Tract Infection Therapeutic Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Respiratory Tract Infection Therapeutic Market, by Drugs, 2022 vs 2030
• 4.3. Respiratory Tract Infection Therapeutic Market, by Disease Indication, 2022 vs 2030
• 4.4. Respiratory Tract Infection Therapeutic Market, by Distribution Channel, 2022 vs 2030
• 4.5. Respiratory Tract Infection Therapeutic Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased reports cases of asthma and respiratory tract infection
    • 5.1.1.2. Changing Lifestyle and geriatric population
    • 5.1.1.3. Increase development of generic drugs and biosimilars in the space
  • 5.1.2. Restraints
    • 5.1.2.1. Seasonal indications and inspections
  • 5.1.3. Opportunities
    • 5.1.3.1. Investment in drug development and commercialization
    • 5.1.3.2. Technology development in drug delivery systems
  • 5.1.4. Challenges
    • 5.1.4.1. Emergence of antimicrobial resistance
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Respiratory Tract Infection Therapeutic Market, by Drugs

• 6.1. Introduction
• 6.2. Antibiotics
• 6.3. Cough Suppressants
• 6.4. Nasal Decongestants
• 6.5. Non-Steroidal Anti-Inflammatory Drugs

7. Respiratory Tract Infection Therapeutic Market, by Disease Indication

• 7.1. Introduction
• 7.2. Lower Respiratory Tract Infection
• 7.3. Upper Respiratory Tract Infection

8. Respiratory Tract Infection Therapeutic Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Respiratory Tract Infection Therapeutic Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Respiratory Tract Infection Therapeutic Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Respiratory Tract Infection Therapeutic Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET RESEARCH PROCESS
• FIGURE 2. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2022 VS 2030
• FIGURE 3. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2022 VS 2030 (%)
• FIGURE 5. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2030 (%)
• FIGURE 6. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
• FIGURE 7. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET DYNAMICS
• FIGURE 9. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 5. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 10. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 13. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 27. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 44. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 47. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 99. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 111. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 114. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 144. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 145. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET LICENSE & PRICING